Literature DB >> 16228237

11C-methionine PET for the diagnosis and management of recurrent pituitary adenomas.

B N T Tang1, M Levivier, M Heureux, D Wikler, N Massager, D Devriendt, P David, N Dumarey, B Corvilain, S Goldman.   

Abstract

PURPOSE: The detection of recurrent pituitary adenoma by magnetic resonance imaging (MRI) is rendered uncertain by the tissue remodelling that follows surgery or radiotherapy. We aimed to evaluate the contribution of PET with 11C-methionine (MET-PET) in the detection and management of recurrent pituitary adenoma.
METHODS: Thirty-three patients with pituitary adenoma were evaluated postoperatively by MET-PET, either because of biological evidence of active residual tumour or because of MRI demonstration of non-functional adenoma growth. We studied 24 secreting adenomas and nine non-functional adenomas.
RESULTS: In 30 patients, MET-PET detected abnormally hypermetabolic tissue. In 14 out of these, MRI did not differentiate between residual tumour and scar formation. In nine of these 14 cases, major therapeutic decisions were undertaken (radiosurgery and surgery). In another group of 16 patients, both MET-PET and MRI detected abnormal tissue. In one case, neither MRI nor MET-PET detected adenomatous tissue. Finally, abnormal tissue was detected in two patients on MRI solely. In these two cases, failure of MET-PET to reveal the adenoma was attributable to concomitant inhibitory therapy. The sensitivity of MET-PET and MRI varied as a function of the tumour type: all non-functional adenomas were localised by both modalities, while MET-PET detected all adrenocorticotropic hormone-secreting adenomas whereas MRI depicted only one of these eight lesions. Fifteen out of 17 patients treated by radiosurgery showed clinical improvement after treatment.
CONCLUSION: We suggest that MET-PET is a sensitive technique complementary to MRI for the detection of residual or recurrent pituitary adenomas. It should gain a place in the efficient management of these tumours.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16228237     DOI: 10.1007/s00259-005-1882-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  45 in total

1.  Magnetic resonance imaging after transsphenoidal surgery of clinically non-functional pituitary macroadenomas and its impact on detecting residual adenoma.

Authors:  P Kremer; M Forsting; G Ranaei; C Wüster; J Hamer; K Sartor; S Kunze
Journal:  Acta Neurochir (Wien)       Date:  2002-05       Impact factor: 2.216

2.  Pituitary adenomas: findings of postoperative MR imaging.

Authors:  E Steiner; E Knosp; C J Herold; J Kramer; R Stiglbauer; K Staniszewski; H Imhof
Journal:  Radiology       Date:  1992-11       Impact factor: 11.105

3.  MR imaging of residual tumor tissue after transsphenoidal surgery of hormone-inactive pituitary macroadenomas: a prospective study.

Authors:  P Kremer; M Forsting; J Hamer; K Sartor
Journal:  Acta Neurochir Suppl       Date:  1996

4.  High-resolution MR imaging of pituitary microadenomas at 1.5 T: experience with Cushing disease.

Authors:  W W Peck; W P Dillon; D Norman; T H Newton; C B Wilson
Journal:  AJR Am J Roentgenol       Date:  1989-01       Impact factor: 3.959

5.  Labelling and metabolism of methionine-methyl-11 C.

Authors:  D Comar; J Cartron; M Maziere; C Marazano
Journal:  Eur J Nucl Med       Date:  1976

6.  Integration of the metabolic data of positron emission tomography in the dosimetry planning of radiosurgery with the gamma knife: early experience with brain tumors. Technical note.

Authors:  M Levivier; D Wikier; S Goldman; P David; T Metens; N Massager; M Gerosa; D Devriendt; F Desmedt; S Simon; P Van Houtte; J Brotchi
Journal:  J Neurosurg       Date:  2000-12       Impact factor: 5.115

7.  Adenohypophysis hormone gene products in 14 pituitary adenomas: analysis by immunohistochemistry and northern blotting.

Authors:  M L Scippo; A Beckers; F Frankenne; M Reznik; A Stevenaert; A Igout; G Hennen
Journal:  Arch Int Physiol Biochim Biophys       Date:  1991-04

8.  [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.

Authors:  G Boni; M Ferdeghini; C R Bellina; F Matteucci; E Castro Lopez; G Parenti; R Canapicchi; R Bianchi
Journal:  Q J Nucl Med       Date:  1995-12

9.  Rapid decrease in amino acid metabolism in prolactin-secreting pituitary adenomas after bromocriptine treatment: a PET study.

Authors:  M Bergström; C Muhr; P O Lundberg; K Bergström; A D Gee; K J Fasth; B Långström
Journal:  J Comput Assist Tomogr       Date:  1987 Sep-Oct       Impact factor: 1.826

10.  Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly.

Authors:  B Swearingen; F G Barker; L Katznelson; B M Biller; S Grinspoon; A Klibanski; N Moayeri; P M Black; N T Zervas
Journal:  J Clin Endocrinol Metab       Date:  1998-10       Impact factor: 5.958

View more
  11 in total

Review 1.  Metabolic In Vivo Visualization of Pituitary Adenomas: a Systematic Review of Imaging Modalities.

Authors:  Amy Yao; Priti Balchandani; Raj K Shrivastava
Journal:  World Neurosurg       Date:  2017-04-28       Impact factor: 2.104

Review 2.  11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas.

Authors:  Tarun Singhal; Tanjore K Narayanan; Viney Jain; Jogeshwar Mukherjee; Joseph Mantil
Journal:  Mol Imaging Biol       Date:  2007-10-24       Impact factor: 3.488

3.  Diagnostic value of 18F-dihydroxyphenylalanine positron emission tomography for growth hormone-producing pituitary adenoma.

Authors:  Takafumi Taguchi; Toshihiro Takao; Yasumasa Iwasaki; Kenichi Oyama; Shozo Yamada; Mari Inoue; Yoshio Terada
Journal:  Pituitary       Date:  2010       Impact factor: 4.107

4.  The combination of 13N-ammonia and 11C-methionine in differentiation of residual/recurrent pituitary adenoma from the pituitary gland remnant after trans-sphenoidal Adenomectomy.

Authors:  Fangling Zhang; Qiao He; Ganhua Luo; Yali Long; Ruocheng Li; Lei Ding; Xiangsong Zhang
Journal:  BMC Cancer       Date:  2021-07-20       Impact factor: 4.430

5.  Selective resection of cushing microadenoma guided by preoperative hybrid 18-fluoroethyl-L-tyrosine and 11-C-methionine PET/MRI.

Authors:  Sven Berkmann; Michel Roethlisberger; Beat Mueller; Mirjam Christ-Crain; Luigi Mariani; Egbert Nitzsche; Freimut Juengling
Journal:  Pituitary       Date:  2021-06-21       Impact factor: 4.107

6.  Molecular Characterization of Growth Hormone-producing Tumors in the GC Rat Model of Acromegaly.

Authors:  Juan F Martín-Rodríguez; Jose L Muñoz-Bravo; Alejandro Ibañez-Costa; Laura Fernandez-Maza; Marcin Balcerzyk; Rocío Leal-Campanario; Raúl M Luque; Justo P Castaño; Eva Venegas-Moreno; Alfonso Soto-Moreno; Alfonso Leal-Cerro; David A Cano
Journal:  Sci Rep       Date:  2015-11-09       Impact factor: 4.379

7.  Positron emission tomography-computed tomography coregistration for diagnosis and intraoperative localization in recurrent nelson syndrome.

Authors:  Eric B Hintz; Jeffery M Tomlin; Vaseem Chengazi; G Edward Vates
Journal:  J Neurol Surg Rep       Date:  2013-05-09

8.  Incidental uptake of (18)F-fluorocholine (FCH) in the head or in the neck of patients with prostate cancer.

Authors:  Marina Hodolic; Virginie Huchet; Sona Balogova; Laure Michaud; Khaldoun Kerrou; Valérie Nataf; Marino Cimitan; Jure Fettich; Jean-Noël Talbot
Journal:  Radiol Oncol       Date:  2014-07-10       Impact factor: 2.991

9.  Cushing's Syndrome in a Patient With Rathke's Cleft Cyst and ACTH Cell Hyperplasia Detected by 11C-Methionine PET Imaging-A Case Presentation.

Authors:  Karol Piotr Sagan; Elzbieta Andrysiak-Mamos; Leszek Sagan; Przemysław Nowacki; Bogdan Małkowski; Anhelli Syrenicz
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-22       Impact factor: 5.555

10.  A remarkable case of thyrotoxicosis initially caused by graves' disease followed by a probable TSHoma - a case report.

Authors:  Mark Quinn; Waiel Bashari; Diarmuid Smith; Mark Gurnell; Amar Agha
Journal:  BMC Endocr Disord       Date:  2020-08-27       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.